Detalhe da pesquisa
1.
Understanding Pharmacokinetic Disconnect in Preclinical Species for 4-Aminoquinolines: Consequences of Low Permeability and High P-glycoprotein Efflux Ratio on Rat and Dog Oral Pharmacokinetics.
J Pharm Sci
; 109(10): 3160-3171, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32565354
2.
Correction to Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.
ACS Med Chem Lett
; 11(6): 1353, 2020 Jun 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32551024
3.
Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer.
ACS Med Chem Lett
; 10(6): 857-862, 2019 Jun 13.
Artigo
Inglês
| MEDLINE | ID: mdl-31223438
4.
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.
J Med Chem
; 62(14): 6482-6494, 2019 07 25.
Artigo
Inglês
| MEDLINE | ID: mdl-31265286
5.
Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.
J Med Chem
; 62(10): 5096-5110, 2019 05 23.
Artigo
Inglês
| MEDLINE | ID: mdl-31013427
6.
Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.
ACS Med Chem Lett
; 9(10): 1039-1044, 2018 Oct 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30344914
7.
Identification of an antibody-based immunoassay for measuring direct target binding of RIPK1 inhibitors in cells and tissues.
Pharmacol Res Perspect
; 5(6)2017 12.
Artigo
Inglês
| MEDLINE | ID: mdl-29226625
8.
Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.
J Med Chem
; 60(4): 1247-1261, 2017 02 23.
Artigo
Inglês
| MEDLINE | ID: mdl-28151659
9.
The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase.
J Med Chem
; 59(10): 4867-80, 2016 05 26.
Artigo
Inglês
| MEDLINE | ID: mdl-27109867